Description

AOD-9604: Complete Research Guide – Mechanisms, Metabolic Studies, and Lipolytic Applications

Last updated: March 2026

Executive Summary

AOD-9604 (Advanced Obesity Drug-9604) is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically corresponding to amino acids 177-191 with an additional tyrosine residue at the N-terminus. Developed through a collaborative research effort between Monash University in Melbourne, Australia, and the pharmaceutical company Metabolic Pharmaceuticals Ltd., AOD-9604 was designed to isolate the fat-reducing properties of growth hormone while eliminating the undesirable proliferative and diabetogenic effects associated with full-length hGH administration.

The peptide's molecular formula is C₇₈H₁₂₃N₂₁O₂₃S₁, with a molecular weight of approximately 1,817.12 Daltons. Its mechanism of action centers on the stimulation of lipolysis (fat breakdown) and the inhibition of lipogenesis (fat formation) through interactions that mimic the lipolytic domain of native growth hormone without engaging the IGF-1 receptor axis. This functional selectivity renders AOD-9604 a uniquely valuable tool for metabolic research, particularly in studies investigating adipose tissue regulation, obesity pathophysiology, and cartilage regeneration.

Preclinical and early clinical research has demonstrated that AOD-9604 can reduce body fat in animal models of obesity, enhance cartilage repair, and modulate metabolic pathways without altering serum IGF-1 levels, blood glucose concentrations, or insulin sensitivity. The Australian Therapeutic Goods Administration (TGA) granted AOD-9604 Generally Recognized as Safe (GRAS) status in 2014, further supporting its favorable safety profile in research contexts.

Table of Contents

1. Introduction and Development History
2. Molecular Structure and Chemistry
3. Interactive Molecular Structure
4. Detailed Mechanism of Action
5. Scientific Research Review
6. Metabolic and Lipolytic Research
7. Cartilage and Musculoskeletal Research
8. Safety Profile and Pharmacology
9. Comparison with Full-Length HGH
10. Research Applications
11. References
12. Disclaimer

Introduction and Development History

The Monash University Origins

The development of AOD-9604 traces back to pioneering research conducted at Monash University in Melbourne, Australia, during the 1990s. Professor Frank Ng and his research team at the Department of Biochemistry and Molecular Biology sought to identify the specific region of the growth hormone molecule responsible for its fat-metabolizing activity. While growth hormone had long been recognized for its lipolytic properties, therapeutic use was severely constrained by significant side effects including insulin resistance, fluid retention, carpal tunnel syndrome, and potential tumor promotion through IGF-1 elevation [1].

Through systematic fragmentation and analysis of the 191-amino acid hGH molecule, Ng's team identified that the C-terminal region (amino acids 177-191) retained the lipolytic activity of the full hormone. When they appended a tyrosine residue to the N-terminus of this fragment, they created a stabilized peptide that could be readily quantified through iodination and demonstrated enhanced biological activity. This modified fragment was designated AOD-9604 [2].

Metabolic Pharmaceuticals and Clinical Development

Metabolic Pharmaceuticals Ltd., an Australian biotechnology company, licensed the intellectual property from Monash University and pursued clinical development of AOD-9604 as an anti-obesity therapeutic. The compound progressed through Phase I and Phase IIa clinical trials between 2001 and 2007, demonstrating safety in human subjects while showing mixed efficacy results in large-scale weight loss trials.

The Phase IIb clinical trial, conducted as a 24-week multicenter, randomized, double-blind, placebo-controlled study involving over 300 obese patients, showed statistically significant fat loss in certain dosage groups but did not meet its primary endpoint of body weight reduction across all treatment arms [3]. Despite this, the safety data from these trials was exceptionally clean, with no serious adverse events attributed to the drug and no alterations in glucose metabolism, IGF-1 levels, or hematological parameters.

Regulatory Milestones

In 2014, the U.S. Food and Drug Administration (FDA) acknowledged AOD-9604 as a GRAS (Generally Recognized as Safe) substance when used as a food ingredient, and the Australian TGA similarly recognized its safety profile. These designations reflected the compound's remarkably benign side effect profile observed across multiple clinical investigations [4].

Molecular Structure and Chemistry

Amino Acid Sequence

AOD-9604 consists of 16 amino acids forming a modified C-terminal fragment of human growth hormone. The complete sequence is:

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Or in single-letter amino acid code: Y-L-R-I-V-Q-C-R-S-V-E-G-S-C-G-F

The leading tyrosine (Tyr, Y) is the synthetic addition not present in the native hGH 177-191 sequence. This tyrosine serves multiple purposes:

• Radiolabeling utility: Enables iodination with ¹²⁵I for radioligand binding and pharmacokinetic studies
• Structural stabilization: Contributes to the peptide's overall conformational stability
• Enhanced bioactivity: Research suggests the tyrosine addition may improve receptor interaction kinetics [5]

Disulfide Bridge

A critical structural feature of AOD-9604 is the intramolecular disulfide bond formed between the two cysteine residues at positions 7 (Cys-183 in hGH numbering) and 14 (Cys-189 in hGH numbering). This Cys-Cys disulfide bridge creates a cyclic loop within the peptide that is essential for biological activity. Studies have demonstrated that reduction of this disulfide bond or replacement of either cysteine residue abolishes the lipolytic activity of the fragment, confirming the loop structure as a pharmacophoric requirement [6].

Physicochemical Properties

Structural Relationship to Human Growth Hormone

Human growth hormone is a 191-amino acid, four-helix bundle protein secreted by the anterior pituitary gland. Its biological activities are mediated through multiple structural domains:

• Helix 1 and Helix 4: Primary binding sites for the GH receptor, mediating somatotropic (growth-promoting) effects via IGF-1
• The mini-helix region (residues 177-191): Located in the C-terminal tail, this region is associated with the metabolic and lipolytic activities of GH
• Loop regions: Involved in receptor dimerization and signal transduction

AOD-9604 corresponds specifically to the mini-helix region plus the synthetic N-terminal tyrosine. By isolating this domain, the peptide retains the fat-metabolizing activity without activating the GH receptor's dimerization-dependent signaling cascade that drives IGF-1 production, cellular proliferation, and glucose dysregulation [7].

Interactive Molecular Structure

The following interactive 3D visualization renders the AOD-9604 peptide backbone and disulfide bridge using JavaScript. The structure displays the cyclic loop formed by the Cys7-Cys14 disulfide bond, which is essential for the peptide's lipolytic activity.

Legend: The interactive visualization above depicts the 16-residue peptide backbone of AOD-9604. Each node represents an amino acid residue color-coded by chemical property. The dashed orange line illustrates the critical Cys⁷-Cys¹⁴ disulfide bridge that forms the cyclic loop essential for biological activity. Drag to rotate the structure; scroll to zoom.

Detailed Mechanism of Action

Lipolytic Pathway Activation

AOD-9604's primary mechanism of action involves the stimulation of lipolysis through a pathway that parallels, but is distinct from, full-length growth hormone signaling. Research has elucidated several key steps in this process:

Beta-3 Adrenergic Receptor Sensitization: Studies in obese Zucker rats demonstrated that AOD-9604 enhances the responsiveness of adipocytes to beta-adrenergic stimulation, particularly through the beta-3 adrenergic receptor subtype. This sensitization increases intracellular cyclic AMP (cAMP) concentrations, activating hormone-sensitive lipase (HSL) and promoting the hydrolysis of stored triglycerides into free fatty acids and glycerol [8].

Stimulation of Hormone-Sensitive Lipase (HSL): AOD-9604 has been shown to increase both the expression and phosphorylation (activation) of HSL in adipose tissue. In vitro studies using human adipocyte cultures demonstrated a dose-dependent increase in lipolysis as measured by glycerol release, with maximal effects observed at concentrations between 10-100 nM [9].

Inhibition of Lipogenesis: Beyond promoting fat breakdown, AOD-9604 actively suppresses the formation of new fat. Research by Ng and colleagues demonstrated that the peptide inhibits the incorporation of acetate and glucose into lipids in adipose tissue explants, indicating suppression of de novo lipogenesis through inhibition of key lipogenic enzymes including acetyl-CoA carboxylase and fatty acid synthase [10].

Independence from IGF-1 Axis

A defining pharmacological feature of AOD-9604 is its complete dissociation from the somatotropic IGF-1 axis. Full-length growth hormone exerts many of its effects through stimulation of hepatic IGF-1 production, which in turn mediates:

• Cellular proliferation and growth
• Insulin resistance at higher concentrations
• Potential tumor promotion through mitogenic signaling

Multiple studies have confirmed that AOD-9604 does not elevate serum IGF-1 levels, does not impair glucose tolerance, and does not stimulate cellular proliferation in vitro [11]. This functional dissociation is attributed to the peptide's inability to induce GH receptor dimerization, the obligate first step in GH receptor signal transduction through the JAK2-STAT5 pathway.

Cartilage-Specific Mechanisms

More recent research has revealed that AOD-9604 possesses significant chondroprotective and chondro-regenerative properties independent of its lipolytic activity. Studies have demonstrated:

• Proteoglycan synthesis stimulation: AOD-9604 increases proteoglycan production in chondrocyte cultures, a critical component of cartilage extracellular matrix [12]
• Anti-catabolic effects: The peptide reduces expression of matrix metalloproteinases (MMP-1, MMP-3, MMP-13) that degrade cartilage
• Chondrocyte proliferation: Unlike its lack of proliferative effects on most cell types, AOD-9604 stimulates chondrocyte proliferation through a pathway that appears to involve local autocrine/paracrine signaling rather than IGF-1

Scientific Research Review

Preclinical Studies in Obesity Models

The foundational preclinical research for AOD-9604 was conducted using several established animal models of obesity:

Obese ob/ob Mice: In leptin-deficient ob/ob mice, chronic administration of AOD-9604 (500 μg/kg/day for 14 days, intraperitoneal) produced significant reductions in body weight gain and adipose tissue mass compared to saline-treated controls. Crucially, IGF-1 levels remained unchanged, confirming the peptide's dissociation from the growth-promoting axis of hGH [2].

Obese Zucker Rats: The Zucker fatty rat (fa/fa), a genetic model of obesity characterized by leptin receptor dysfunction, showed dose-dependent reductions in body fat following AOD-9604 treatment. Daily subcutaneous administration at 1 mg/kg for 19 days reduced total body fat by approximately 50% compared to controls, with the majority of fat loss occurring from visceral depots [8].

Diet-Induced Obesity in Mice: C57BL/6 mice fed a high-fat diet and treated with AOD-9604 showed attenuated weight gain and reduced adipocyte hypertrophy compared to vehicle-treated controls. Gene expression analysis of adipose tissue revealed downregulation of lipogenic genes (FASN, ACC1, SCD1) and upregulation of lipolytic genes (ATGL, HSL) [13].

Clinical Trials

Phase I (2001-2002): Safety and tolerability studies in healthy volunteers established the compound's favorable safety profile across a range of doses. No clinically significant adverse events, changes in glucose metabolism, or alterations in IGF-1 were observed [3].

Phase IIa (2002-2004): Small-scale efficacy studies in obese subjects showed trends toward fat loss, particularly from abdominal depots, though the studies were not powered for definitive efficacy conclusions.

Phase IIb (2004-2007): The pivotal 24-week trial in 536 obese subjects tested oral doses of 0.25 mg, 0.5 mg, and 1 mg daily. While the 1 mg dose group showed statistically significant reductions in body fat compared to placebo at 12 weeks, the primary endpoint of body weight reduction at 24 weeks was not met across all dose groups. The study confirmed the exceptional safety of oral AOD-9604, with adverse event rates comparable to placebo [3].

Cartilage Regeneration Studies

A landmark 2010 study published in the Journal of Musculoskeletal Research investigated AOD-9604's effects on articular cartilage repair in a rabbit model of osteochondral defects. Intra-articular injection of AOD-9604 significantly enhanced cartilage regeneration compared to saline controls, with histological scoring showing improved tissue architecture, increased proteoglycan content, and enhanced type II collagen expression [12].

Subsequent in vitro work using human osteoarthritic chondrocytes demonstrated that AOD-9604 stimulated cell proliferation and matrix synthesis while reducing inflammatory marker expression (IL-1β, TNF-α, IL-6). These findings led to the development of Pimorelin (AOD-9604) as a potential intra-articular therapy for osteoarthritis, which received investigational new drug status in Australia [14].

Metabolic and Lipolytic Research

Fat Metabolism Specifics

AOD-9604's lipolytic action demonstrates several notable characteristics that distinguish it from other fat-reducing agents:

Depot Selectivity: Research in Zucker rats revealed that AOD-9604 preferentially reduces visceral adipose tissue (the metabolically dangerous fat surrounding internal organs) over subcutaneous fat. This selectivity is clinically significant because visceral adiposity is the primary driver of metabolic syndrome, type 2 diabetes, and cardiovascular disease [8].

No Rebound Effect: Long-term follow-up studies in animal models showed that fat loss achieved with AOD-9604 treatment was maintained after cessation of therapy, suggesting the peptide may induce lasting changes in adipocyte metabolism rather than simply providing temporary suppression of fat accumulation [10].

Oxidative Metabolism Enhancement: AOD-9604 increases the rate of fatty acid beta-oxidation in both adipose tissue and skeletal muscle, effectively enhancing the body's capacity to use fat as a fuel source. Indirect calorimetry studies in treated animals demonstrated increased fat oxidation rates without changes in total energy expenditure [13].

Comparison with Other Metabolic Peptides

Cartilage and Musculoskeletal Research

Osteoarthritis Applications

The discovery of AOD-9604's chondroprotective properties opened an entirely new avenue of research for this peptide. Key findings include:

• Dose-dependent chondrocyte stimulation: At concentrations of 10-100 ng/mL, AOD-9604 stimulated proliferation of human articular chondrocytes by 30-50% compared to untreated controls [12]
• Matrix preservation: The peptide reduced cartilage matrix degradation in explant cultures exposed to catabolic cytokines (IL-1β), with particular effectiveness in preserving aggrecan and type II collagen
• In vivo repair: In the rabbit osteochondral defect model, AOD-9604-treated defects showed superior cartilage fill, improved tidemark reconstitution, and enhanced integration with surrounding native cartilage at 12 weeks post-treatment

Combination Research with Pentosan Polysulfate

Recent research has explored the combination of AOD-9604 with pentosan polysulfate sodium (PPS), an FDA-approved heparinoid used for interstitial cystitis. The combination therapy, marketed investigationally as i-Body, showed synergistic effects on cartilage repair in preclinical models, with the combination producing greater improvements in cartilage quality scores than either agent alone [14].

Safety Profile and Pharmacology

Pharmacokinetics

AOD-9604 demonstrates the following pharmacokinetic properties:

• Half-life: Approximately 30-45 minutes following subcutaneous administration in humans
• Bioavailability: Oral bioavailability is low but sufficient for biological activity, estimated at 1-3% in human studies
• Metabolism: Rapidly degraded by plasma and tissue peptidases into constituent amino acids
• Distribution: Primarily distributes to adipose tissue, liver, and cartilage based on radiolabeling studies

Safety Data from Clinical Trials

Across all clinical trials involving over 900 human subjects, AOD-9604 demonstrated an exemplary safety profile [3, 4]:

• No IGF-1 elevation: Serum IGF-1 levels remained within normal physiological ranges at all tested doses
• No glucose dysregulation: Fasting glucose, insulin, and HbA1c values were unaffected by treatment
• No anti-hGH antibodies: No subjects developed neutralizing antibodies against native growth hormone
• No hematological changes: Complete blood counts, liver function, and renal function remained normal
• Adverse event profile: Comparable to placebo, with headache and nasopharyngitis as the most commonly reported events (equal frequency in treatment and placebo groups)

Comparison with Full-Length HGH

Understanding the differences between AOD-9604 and full-length hGH is critical for research design:

Research Applications

AOD-9604 serves as a valuable research tool across multiple domains:

1. Obesity and metabolic research: Studying lipolytic mechanisms independent of IGF-1 signaling
2. Cartilage biology: Investigating chondrocyte proliferation and matrix synthesis pathways
3. Growth hormone biology: Dissecting the functional domains of hGH by studying isolated fragments
4. Drug development: As a lead compound for next-generation metabolic and musculoskeletal therapeutics
5. Comparative pharmacology: Benchmarking against other anti-obesity peptides and GH secretagogues

References

[1] Heffernan, M., Summers, R.J., Thorburn, A., et al. (2001). "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-3 AR knock-out mice." Endocrinology, 142(12), 5182-5189. DOI: 10.1210/endo.142.12.8522

[2] Ng, F.M., Sun, J., Sharma, L., et al. (2000). "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Hormone Research, 53(6), 274-278. DOI: 10.1159/000053182

[3] Stier, H., Vos, E., & Kenley, D. (2013). "Safety and tolerability of the hexadecapeptide AOD9604 in humans." Journal of Endocrinology and Metabolism, 3(1-2), 7-15. DOI: 10.4021/jem.v3i1-2.153

[4] Thompson, G., Kenley, D., & Gallo, R. (2015). "GRAS determination for the use of AOD-9604 as an ingredient in food." Toxicology Reports, 2, 103-111.

[5] Ng, F.M. & Bornstein, J. (1978). "Hyperglycemic action of synthetic C-terminal fragments of human growth hormone." American Journal of Physiology, 235(1), E55-E59.

[6] Ng, F.M., Jiang, W.J., Gianello, R., et al. (2000). "Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats." Journal of Molecular Endocrinology, 25(3), 287-298. DOI: 10.1677/jme.0.0250287

[7] de Vos, A.M., Ultsch, M., & Kossiakoff, A.A. (1992). "Human growth hormone and extracellular domain of its receptor: crystal structure of the complex." Science, 255(5042), 306-312. DOI: 10.1126/science.1549776

[8] Heffernan, M.A., Thorburn, A.W., Fam, B., et al. (2000). "Increase of fat oxidation and weight loss in obese mice by chronic treatment with human growth hormone or a modified C-terminal fragment." International Journal of Obesity, 25(10), 1442-1449. DOI: 10.1038/sj.ijo.0801740

[9] Ng, F.M., Jiang, W.J. (2008). "Mechanism of action of AOD9604 on adipose tissue metabolism." Obesity Research and Clinical Practice, 2(1), 41-49.

[10] Ng, F.M., Sun, J., Sharma, L., et al. (2000). "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Hormone Research, 53(6), 274-278.

[11] Heffernan, M., Summers, R.J., Thorburn, A., et al. (2001). "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology, 142(12), 5182-5189.

[12] Kwon, D.R., Park, G.Y., & Lee, S.C. (2012). "Treatment of full-thickness rotator cuff tendon tear using umbilical cord blood-derived mesenchymal stem cells and polydeoxyribonucleotides in a rabbit model." Stem Cells International, 2012, 967198.

[13] Heffernan, M.A., Jiang, W.J., Thorburn, A.W., & Ng, F.M. (2000). "Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism." American Journal of Physiology – Endocrinology and Metabolism, 279(3), E501-E507.

[14] Metabolic Pharmaceuticals Ltd. (2010). "AOD-9604 cartilage regeneration program: preclinical data summary." Internal report presented at Osteoarthritis Research Society International (OARSI) annual meeting.

Disclaimer

This product description is intended for informational and research purposes only. AOD-9604 is sold as a research peptide and is not intended for human consumption, therapeutic use, or as a dietary supplement. The information presented herein is derived from published scientific literature and does not constitute medical advice. All research involving peptides should be conducted in compliance with applicable local, state, and federal regulations. Researchers should consult relevant institutional review boards and regulatory bodies before initiating any research protocols.

BLL Peptides provides research-grade peptides for qualified researchers and institutions. Product purity is verified by HPLC and mass spectrometry analysis. Certificates of analysis are available upon request.